<p>制药行业在我们日常生活中扮演着至关重要的角色。从我们需要的救命药物，到日常的止痛或过敏药物，大型制药公司在提供我们所需的药物方面发挥着重要作用，让我们能够保持快乐和健康。</p>
<p>围绕这一行业，大多数投资者的关注要么是负面的（与美国高昂的药品价格有关），要么是放在创新治疗各种退行性疾病上，如阿尔茨海默病、糖尿病治疗、减肥药物和各种癌症治疗。许多这些特定业务线确实非常赚钱，并且对患者有着很高的内在和显性价值，因此可以相应地收费。</p>
<p>因此，那些能够建立可持续的药物管道并继续受益于专利和其他保护措施的公司，将有很多钱可赚。专家建议，整个制药行业到 2028 年的预计收入可能达到 1.6 万亿美元，这意味着这是一个值得分一杯羹的大蛋糕。</p>
<p>对于那些寻找这一行业最佳投资机会的人，这里是我目前的三大首选。</p>
<h2>本文要点：</h2>
<ul>
<li>大型制药公司可能在新闻中声名狼藉，但它们继续产生可预测且持续增长的利润。</li>
<li>以下是未来几年中玩转这一行业长期潜力的三种最大、最好的方式。</li>
<li>如果你正在寻找潜力巨大的股票，请务必获取我们全新的 “下一个英伟达” 报告的免费副本。其中包括我们确信具有 10 倍潜力的软件股票。</li>
</ul>
<h2>艾伯维（ABBV）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2022/10/imageForEntry31-0VG.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2022/10/imageForEntry31-0VG.jpg"/></p>
<p>艾伯维公司总部外的标志</p>
<p><strong>艾伯维</strong>（NYSE: ABBV）是一家顶尖的制药巨头，今年股价飙升。该公司的股价今年上涨约 60%，更令人印象深刻的是，股价在过去五年里飙升了超过 730%。这种回报是投资者可能期望从快速增长的初创公司而不是市值接近 8000 亿美元的公司看到的。</p>
<p>艾伯维之所以声名鹊起，主要源自其热门药物提尔齐帕肽，该药物以蒙加罗的名义治疗糖尿病，并最近获得了减肥药物泽普邦的批准。</p>
<p>据分析师预计，该药物的销售额预计将达到约 500 亿美元，预计随着时间的推移可能会增加其他适应症。我见过它对他人的影响，并可以证明这种药物在其性质上是革命性的。但是，对于如此革命性的药物，肯定会有来自其他公司的竞争，而艾伯维已经看到了这一点。</p>
<p>也就是说，鉴于目前的短缺和保险公司价格上涨的预期，这是一种在市场上肯定具有充足定价权的药物。该公司继续以令人印象深刻的销售额吸引增长型投资者，截至 6 月 30 日的季度报告显示，销售额达到 113 亿美元。这相当于同比增长 36%，年初至今增长 31%。</p>
<p>我认为，鉴于艾伯维强大的药物管道，这种势头可以在长期内持续下去。这是我认为目前值得投资的长期赢家。</p>
<h2>黎利制药（LLY）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2022/10/imageForEntry9-02k.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2022/10/imageForEntry9-02k.jpg"/></p>
<p>艾伯维办公楼</p>
<p>在 7 月 25 日，制药巨头 <strong>艾伯维</strong>（NYSE: ABBV）是那些根据公司的免疫药物销售强劲业绩而提高 2024 年利润预测的顶级参与者之一。艾伯维报告的季度业绩超过了华尔街的预期，推动其股价创下历史新高。作为报告的一部分，这家药品巨头增加了 10 美分的盈利预期，预计本财年每股盈利在 10.71 美元至 10.91 美元之间。</p>
<p>这些业绩确实令人印象深刻，但我认为公司整体股息概况并没有得到足够的关注。艾伯维股票目前的股息率为 3.2%，是我认为值得长期持有的分红制药巨头之一。部分原因是这家药品巨头在过去十年里将股息支付增加了 270%，远远超过大多数同行。因此，在这个高利润空间中寻找收入的投资者肯定可以依靠这支股票获得出色的总回报。</p>
<p>艾伯维继续有效地重新投资其利润，2019 年推出了治疗牛皮癣的斯凯瑞兹和治疗关节炎的林沃克，这两者在同一时期共产生了 73 亿美元的销售额。从长期来看，这是我认为值得在这里持有的顶级制药股票。</p>
<h2>默克（MRK）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2022/05/imageForEntry9-umf.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2022/05/imageForEntry9-umf.jpg"/></p>
<p>默克办公楼</p>
<p><strong>默克</strong>（NYSE: MRK）是另一家美国主要制药公司，专注于提供各种疫苗和抗癌药物。值得注意的是，截至去年，该公司的管道中有 52 种药物，而且这个数字还在增长。此外，默克的主要抗癌药物在过去一年中创造了 263 亿美元的销售额。这代表了 16% 的同比增长，并使公司在这一核心领域处于有利位置。</p>
<p>此外，该公司继续通过收购早期药物并将其打造成畅销品来增强其产品组合。默克收购 EyeBio 开发视网膜治疗药物以及收购 Elanco 水产业务扩展其动物保健业务，巩固了其在这些市场的领先地位。</p>
<p>该公司还通过在 2023 年投入 305 亿美元用于研发，巩固了其在行业中的领先地位。其庞大的基础设施使得药品和疫苗的生产成本更具竞争力，增强了其竞争优势。分析师仍然持乐观态度，预计未来 12 个月的中位价格目标为 140 美元，暗示着相对当前价格的 20% 上涨。</p>
<p>我认为这家顶级制药公司将是长期赢家，但这不仅仅是我的看法。华尔街似乎也对此持乐观态度。我喜欢这一点。</p>
<h2><strong>参加这个退休问卷，立即与顾问匹配（赞助内容）</strong></h2>
<p>您准备好退休了吗？规划退休可能让人感到不知所措，这就是为什么今天与一位受托人理财顾问讨论您的目标可能是个好主意。</p>
<p>首先，从 SmartAsset 的这个退休问卷开始，它将在 5 分钟内为您匹配最多 3 位服务您所在地区及周边地区的理财顾问。Smart Asset 目前每月为超过 5 万人提供匹配服务。</p>
<p>立即点击这里开始。</p>
<p>这篇文章首发于 24/7 Wall St.，介绍 2024 年 10 月值得购买的 3 家顶级制药公司股票。</p>

礼来

艾伯维

<p>制药行业对日常健康至关重要，创新治疗方案备受投资者关注。专家预测，到 2028 年，该行业的收入可能达到 1.6 万亿美元。热门股票选择包括礼来（LLY），由于其糖尿病和减肥药物 Mounjaro，今年股价上涨了 60%；以及艾伯维（ABBV），该公司提高了利润预测，并提供 3.2% 的股息率。这两家公司在一个利润丰厚的市场中处于长期增长的有利位置</p>

<p>The pharmaceutical industry plays a crucial role in most of our everyday lives. From life-saving medication we need when we need it, to everyday pain remediation or allergy medications, big pharma companies have played a big role in providing the medicines we all need to stay happy and healthy on a daily basis.</p>
<div class="lb-trans"><p>制药行业在我们日常生活中扮演着至关重要的角色。从我们需要的救命药物，到日常的止痛或过敏药物，大型制药公司在提供我们所需的药物方面发挥着重要作用，让我们能够保持快乐和健康。</p>
</div><p>Most investor attention around this sector has either been negative (tied to higher prices in the U.S.) or has been placed on innovative treatments for various degenerative diseases such as Alzheimer’s, diabetes treatments, weight loss drugs and various cancer treatments. Many of these particular business lines are certainly very lucrative, and have a high implicit and explicit value for their patients, and can be charged for accordingly.</p>
<div class="lb-trans"><p>围绕这一行业，大多数投资者的关注要么是负面的（与美国高昂的药品价格有关），要么是放在创新治疗各种退行性疾病上，如阿尔茨海默病、糖尿病治疗、减肥药物和各种癌症治疗。许多这些特定业务线确实非常赚钱，并且对患者有着很高的内在和显性价值，因此可以相应地收费。</p>
</div><p>Thus, companies that are able to build out sustainable drug pipelines and continue to benefit from patents and other protective measures this sector benefits from, there’s a lot of money to be made. Experts suggest that the entire pharma sector could see projected revenues hit $1.6 trillion by 2028, meaning this is a big pie to try to take a bite out of.</p>
<div class="lb-trans"><p>因此，那些能够建立可持续的药物管道并继续受益于专利和其他保护措施的公司，将有很多钱可赚。专家建议，整个制药行业到 2028 年的预计收入可能达到 1.6 万亿美元，这意味着这是一个值得分一杯羹的大蛋糕。</p>
</div><p>For those looking for the best bets this sector has to offer, here are three of my top picks right now.</p>
<div class="lb-trans"><p>对于那些寻找这一行业最佳投资机会的人，这里是我目前的三大首选。</p>
</div><h2>Key Points About This Article:</h2>
<ul>
<li>Big pharma companies may be getting a bad rep in the news, but they continue to pump out predictable and growing profits over time.</li>
<li>Here are three of the biggest and best ways to play the long-term potential growth of this sector in the coming years.</li>
<li>If you’re looking for some stocks with huge potential, make sure to grab a free copy of our <strong>brand-new “The Next NVIDIA” report</strong>. It features a software stock we’re confident has 10X potential.</li>
</ul>
<div class="lb-trans"><h2>本文要点：</h2>
<ul>
<li>大型制药公司可能在新闻中声名狼藉，但它们继续产生可预测且持续增长的利润。</li>
<li>以下是未来几年中玩转这一行业长期潜力的三种最大、最好的方式。</li>
<li>如果你正在寻找潜力巨大的股票，请务必获取我们全新的 “下一个英伟达” 报告的免费副本。其中包括我们确信具有 10 倍潜力的软件股票。</li>
</ul>
</div><h2>Eli Lilly (LLY)</h2>
<div class="lb-trans"><h2>艾伯维（ABBV）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2022/10/imageForEntry31-0VG.jpg" alt="" original-src="https://247wallst.com/wp-content/uploads/2022/10/imageForEntry31-0VG.jpg"/></p>
<p>An Eli Lilly sign outside the company’s corporate offices</p>
<div class="lb-trans"><p>艾伯维公司总部外的标志</p>
</div><p><strong>Eli Lilly</strong> (NYSE:LLY) is a top pharmaceutical giant that is absolutely rocketing higher this year. The company’s share price hassurged by approximately 60% this year, and even more impressively, the stock has skyrocketed more than 730% over the past five years. Those are the kinds of returns investors might expect to see from a fast-growing startup, not a company with a market capitalization near $800 billion.</p>
<div class="lb-trans"><p><strong>艾伯维</strong>（NYSE: ABBV）是一家顶尖的制药巨头，今年股价飙升。该公司的股价今年上涨约 60%，更令人印象深刻的是，股价在过去五年里飙升了超过 730%。这种回报是投资者可能期望从快速增长的初创公司而不是市值接近 8000 亿美元的公司看到的。</p>
</div><p>Eli Lilly’s ride to investor fame has largely stemmed from its popular drug, tirzepatide, which treats diabetes under the name Mounjaro and has recently been approved for weight loss as Zepbound.</p>
<div class="lb-trans"><p>艾伯维之所以声名鹊起，主要源自其热门药物提尔齐帕肽，该药物以蒙加罗的名义治疗糖尿病，并最近获得了减肥药物泽普邦的批准。</p>
</div><p>This drug is expected to see peak sales of around $50 billion according to analysts, with expectations that additional indications could be added on over time. I’ve seen the impact on others and can vouch that this drug is revolutionary in its nature. But with such a revolutionary drug, there will most certainly be competition from others, which Eli Lilly is already seeing.</p>
<div class="lb-trans"><p>据分析师预计，该药物的销售额预计将达到约 500 亿美元，预计随着时间的推移可能会增加其他适应症。我见过它对他人的影响，并可以证明这种药物在其性质上是革命性的。但是，对于如此革命性的药物，肯定会有来自其他公司的竞争，而艾伯维已经看到了这一点。</p>
</div><p>That said, given current shortages and expectations of pricing increases for insurance companies, this is a drug that could certainly have plenty of pricing power in the market. The company has continued to attract growth investors with impressive sales, reporting $11.3 billion for the quarter ending June 30. This amounted to a 36% increase year-over-year, and a 31% rise year-to-date.</p>
<div class="lb-trans"><p>也就是说，鉴于目前的短缺和保险公司价格上涨的预期，这是一种在市场上肯定具有充足定价权的药物。该公司继续以令人印象深刻的销售额吸引增长型投资者，截至 6 月 30 日的季度报告显示，销售额达到 113 亿美元。这相当于同比增长 36%，年初至今增长 31%。</p>
</div><p>I think this momentum can continue over the long-term, given Eli Lilly’s strong drug pipeline. This is a long-term winner I think is worth the plump valuation right now.</p>
<div class="lb-trans"><p>我认为，鉴于艾伯维强大的药物管道，这种势头可以在长期内持续下去。这是我认为目前值得投资的长期赢家。</p>
</div><h2>AbbVie (ABBV)</h2>
<div class="lb-trans"><h2>黎利制药（LLY）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2022/10/imageForEntry9-02k.jpg" alt="" original-src="https://247wallst.com/wp-content/uploads/2022/10/imageForEntry9-02k.jpg"/></p>
<p>An AbbVie office building</p>
<div class="lb-trans"><p>艾伯维办公楼</p>
</div><p>On July 25, pharma giant <strong>AbbVie</strong> (NYSE:ABBV) was among the top players that raised their 2024 profit forecast following strong results driven by the company’s immunology drug sales. AbbVie reported quarterly results that surpassed Wall Street expectations, propelling its shares to a record high. As part of its report, the drug giant increased its earnings estimate by 10 cents, projecting between $10.71 and $10.91 per share for this fiscal year.</p>
<div class="lb-trans"><p>在 7 月 25 日，制药巨头 <strong>艾伯维</strong>（NYSE: ABBV）是那些根据公司的免疫药物销售强劲业绩而提高 2024 年利润预测的顶级参与者之一。艾伯维报告的季度业绩超过了华尔街的预期，推动其股价创下历史新高。作为报告的一部分，这家药品巨头增加了 10 美分的盈利预期，预计本财年每股盈利在 10.71 美元至 10.91 美元之间。</p>
</div><p>Those results certainly were impressive, but I don’t think enough attention has been paid to the company’s overall dividend profile. AbbVie stock currently yields 3.2%, and is among the dividend-paying pharma giants I think is worth owning for the long-term. That’s in part due to the fact this drug giant has increased increased its dividend payout by 270% over the past decade, far surpassing most of its peers. Thus, those looking for an income-generating investment in this highly-profitable space can certainly bank on this stock for excellent total returns.</p>
<div class="lb-trans"><p>这些业绩确实令人印象深刻，但我认为公司整体股息概况并没有得到足够的关注。艾伯维股票目前的股息率为 3.2%，是我认为值得长期持有的分红制药巨头之一。部分原因是这家药品巨头在过去十年里将股息支付增加了 270%，远远超过大多数同行。因此，在这个高利润空间中寻找收入的投资者肯定可以依靠这支股票获得出色的总回报。</p>
</div><p>AbbVie continues to effectively reinvest its profits, launching Skyrizi for psoriasis and Rinvoq for arthritis in 2019, which together generated $7.3 billion in sales during the same period. Over the long-term, this is a top pharmaceutical stock I think is worth owning here.</p>
<div class="lb-trans"><p>艾伯维继续有效地重新投资其利润，2019 年推出了治疗牛皮癣的斯凯瑞兹和治疗关节炎的林沃克，这两者在同一时期共产生了 73 亿美元的销售额。从长期来看，这是我认为值得在这里持有的顶级制药股票。</p>
</div><h2>Merck (MRK)</h2>
<div class="lb-trans"><h2>默克（MRK）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2022/05/imageForEntry9-umf.jpg" alt="" original-src="https://247wallst.com/wp-content/uploads/2022/05/imageForEntry9-umf.jpg"/></p>
<p>A Merck office building</p>
<div class="lb-trans"><p>默克办公楼</p>
</div><p><strong>Merck</strong>(NYSE:MRK) is another major U.S. pharmaceutical company that is focused on providing a range of vaccines and cancer care drugs. Notably, the company has 52 drugs in its pipeline as of last year, and the number is growing. Additionally, Merck’s top cancer drug generated $26.3 billion in sales over the past year. This represented 16% year-over-year growth, and positions the company well in this core segment.</p>
<div class="lb-trans"><p><strong>默克</strong>（NYSE: MRK）是另一家美国主要制药公司，专注于提供各种疫苗和抗癌药物。值得注意的是，截至去年，该公司的管道中有 52 种药物，而且这个数字还在增长。此外，默克的主要抗癌药物在过去一年中创造了 263 亿美元的销售额。这代表了 16% 的同比增长，并使公司在这一核心领域处于有利位置。</p>
</div><p>Furthermore, the company continues to enhance its portfolio via acquiring early-stage drugs and turning them into blockbusters. Merck’s acquisition of EyeBio to develop retinal treatments is among the key deals worth noting, as well as the company’s expansion of its Animal Health segment through the purchase of Elanco’s aqua business, reinforcing its leadership in these markets.</p>
<div class="lb-trans"><p>此外，该公司继续通过收购早期药物并将其打造成畅销品来增强其产品组合。默克收购 EyeBio 开发视网膜治疗药物以及收购 Elanco 水产业务扩展其动物保健业务，巩固了其在这些市场的领先地位。</p>
</div><p>The company also solidified its industry leadership with a $30.5 billion investment in research and development in 2023. Its expansive infrastructure enables cost-effective drug and vaccine production, enhancing its competitive advantage. Analysts remain optimistic, with a 12-month median price target of $140, suggesting a 20% upside from here.</p>
<div class="lb-trans"><p>该公司还通过在 2023 年投入 305 亿美元用于研发，巩固了其在行业中的领先地位。其庞大的基础设施使得药品和疫苗的生产成本更具竞争力，增强了其竞争优势。分析师仍然持乐观态度，预计未来 12 个月的中位价格目标为 140 美元，暗示着相对当前价格的 20% 上涨。</p>
</div><p>I think this top pharma stock will be a long-term winner, but that’s not just my view. Wall Street seems to be aboard this train. I like that.</p>
<div class="lb-trans"><p>我认为这家顶级制药公司将是长期赢家，但这不仅仅是我的看法。华尔街似乎也对此持乐观态度。我喜欢这一点。</p>
</div><h2><strong>Take This Retirement Quiz To Get Matched With An Advisor Now (Sponsored)</strong></h2>
<div class="lb-trans"><h2><strong>参加这个退休问卷，立即与顾问匹配（赞助内容）</strong></h2>
</div><p>Are you ready for retirement? Planning for retirement can be overwhelming, that’s why it could be a good idea to speak to a fiduciary financial advisor about your goals today.</p>
<div class="lb-trans"><p>您准备好退休了吗？规划退休可能让人感到不知所措，这就是为什么今天与一位受托人理财顾问讨论您的目标可能是个好主意。</p>
</div><p>Start by taking this retirement quiz right here from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes. Smart Asset is now matching over 50,000 people a month.</p>
<div class="lb-trans"><p>首先，从 SmartAsset 的这个退休问卷开始，它将在 5 分钟内为您匹配最多 3 位服务您所在地区及周边地区的理财顾问。Smart Asset 目前每月为超过 5 万人提供匹配服务。</p>
</div><p>Click here now to get started.</p>
<div class="lb-trans"><p>立即点击这里开始。</p>
</div><p>The post 3 Top Pharma Stocks to Buy in October 2024 appeared first on 24/7 Wall St..</p>
<div class="lb-trans"><p>这篇文章首发于 24/7 Wall St.，介绍 2024 年 10 月值得购买的 3 家顶级制药公司股票。</p>
</div>

2024 年 10 月值得购买的三大制药股票